Market Research Logo

Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2019

Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2019

Summary

GlobalData's clinical trial report, “Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2019 provides an overview of Clostridium difficile Infections (Clostridium difficile Associated Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Clostridium difficile Infections (Clostridium difficile Associated Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Table Figure 1: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Region (%), 2019*
    • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Region, 2019*
    • Clinical Trials and Average Enrollment by Country
      • Table Figure 2: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
      • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
      • Table Figure 3: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
      • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
        • Table Figure 4: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019*
        • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019*
      • Top Five Countries Contributing to Clinical Trials in Europe
        • Table Figure 5: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019*
        • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019*
      • Top Countries Contributing to Clinical Trials in North America
        • Table Figure 6: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2019*
        • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, North America, Top Countries, 2019*
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
        • Table Figure 7: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019*
        • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019*
      • Top Five Countries Contributing to Clinical Trials in Central and South America
        • Table Figure 8: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019*
        • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019*
  • Clinical Trials by G7 Countries: Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials
    • Table Figure 9: Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials, G7 Countries (%), 2019*
    • Table Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials, G7 Countries (%), 2019*
  • Clinical Trials by Phase in G7 Countries
    • Table Figure 10: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
    • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
  • Clinical Trials in G7 Countries by Trial Status
    • Table Figure 11: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
    • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
  • Clinical Trials by E7 Countries: Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials
    • Table Figure 12: Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials, E7 Countries (%), 2019*
    • Table Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials, E7 Countries (%), 2019*
  • Clinical Trials by Phase in E7 Countries
    • Table Figure 13: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
    • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
  • Clinical Trials in E7 Countries by Trial Status
    • Table Figure 14: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
    • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
  • Clinical Trials by Phase
    • Table Figure 15: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2019*
    • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Phase, 2019*
    • In Progress Trials by Phase
      • Table Figure 16: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019*
      • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2019*
  • Clinical Trials by Trial Status
    • Table Figure 17: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2019*
    • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2019*
  • Clinical Trials by End Point Status
    • Table Figure 18: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2019*
    • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2019*
  • Subjects Recruited Over a Period of Time
    • Table Figure 19: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
    • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Clinical Trials by Sponsor Type
    • Table Figure 20: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019*
    • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Market, Global, Clinical Trial by Sponsor Type, 2019*
  • Prominent Sponsors
    • Table Figure 21: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
    • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
    • Top Companies Participating in Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials
      • Table Figure 22: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
      • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
  • Prominent Drugs
    • Table Figure 23: Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
    • Table Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
  • Latest Clinical Trials News on Clostridium difficile Infections (Clostridium difficile Associated Disease)
    • Mar 20, 2019: Microbiome Health Index Platform to be presented at Gut Microbiota for Health Summit 2019
    • Feb 27, 2019: Acurx announces first-in-man clinical trial data of ACX-362E for CDI
    • Feb 15, 2019: Summit begins dosing in Phase III trials of ridinilazole
    • Feb 11, 2019: Finch Therapeutics' C. Difficile infection drug gets breakthrough status
    • Jan 31, 2019: Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner
    • Jan 28, 2019: Oragenics receives further validation for lantibiotic compound OG716
    • Jan 24, 2019: MGB Biopharma - FDA and Health Canada clear IND/CTA applications for MGB-BP-3, a novel, potent bactericidal antibiotic targeting clostridium difficile-associated diarrhoea (CDAD)
    • Jan 22, 2019: Emory leads multi-site NIH clinical trial testing fecal transplants for recurrent diarrheal disease
    • Jan 16, 2019: Acurx receives FDA Fast Track Designation for ACX-362E for the treatment of C. difficile infection
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
      • Table Figure 24: GlobalData Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report